SWOT Analysis

Strength: High unmet medical needs and limited treatment options present lucrative growth opportunities.
Weakness: Risks and complications associated with parenteral nutrition and small bowel transplant procedures.
Opportunity: Significant research into new drug therapies, gut modulators, growth factors, and regenerative medicine approaches.
Threats: High cost of immunotherapy treatment, side effects of immunotherapy drugs.

Key Takeaways

The Global Short Bowel Syndrome Market Size is expected to witness high growth, exhibiting CAGR of 11.5% over the forecast period of 2023-2030, due to increasing research and development of novel therapeutics. The market size in 2023 is US$ 188.9 Bn.

Regional analysis: North America currently dominates the global market due to rising prevalence of intestinal disorders and technological advancements. However, Asia Pacific is expected to grow at fastest pace due to rising healthcare spending and expanding medical tourism industry.

Key players operating in the Short Bowel Syndrome market include Shire Plc., Merck & Co., Inc., Real Food Blends, LLC, VectivBio AG, Ardelyx, Inc., Zealand Pharma A/S, GLyPharma Therapeutic, Inc., Naia Pharmaceuticals, Inc., and others.

Key players analysis: Key players operating in the Short Bowel Syndrome market include Shire Plc., Merck & Co., Inc., Real Food Blends, LLC, VectivBio AG, Ardelyx, Inc., Zealand Pharma A/S, GLyPharma Therapeutic, Inc., Naia Pharmaceuticals, Inc.

Read More -  https://www.timessquarereporter.com/health/short-bowel-syndrome-market-connected-with-high-cost-of-immunotherapy-treatment-as-a-part-of-heading